Jim Mazzola

Investor Relations Contact at OUTSET MEDICAL, INC.

Health Technology

Distribution Services

Consumer Services

Profile

Jim Mazzola is currently the Head-Investor Relations at Outset Medical, Inc. Prior to this, he worked as Senior Vice President-Communication at Cardinal Health, Inc. from 2003 to 2008.
He then served as Head-Communication at Halozyme Therapeutics, Inc. and as Senior Vice President-Corporate Marketing at CareFusion Corp.
from 2008 to 2015.
He also worked as Investor Contact at Turning Point Therapeutics, Inc. and as President at CareFusion Foundation.
Mr. Mazzola completed his undergraduate and MBA degrees from the University of Dayton.

Jim Mazzola active positions

Companies	Position	Start
OUTSET MEDICAL, INC.	Investor Relations Contact	2021-12-31

All active positions of Jim Mazzola

Former positions of Jim Mazzola

Companies	Position	End
CAREFUSION CORPORATION	Investor Relations Contact	2015-02-28
CARDINAL HEALTH, INC.	Public Communications Contact	2008-08-31
CareFusion Foundation	President	-
HALOZYME THERAPEUTICS, INC.	Investor Relations Contact	-
TURG POIN	Investor Relations Contact	-

See the detail of Jim Mazzola's experience

Training of Jim Mazzola

University of Dayton

Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jim Mazzola's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	3
CARDINAL HEALTH, INC.	Distribution Services
HALOZYME THERAPEUTICS, INC.	Health Technology
OUTSET MEDICAL, INC.	Health Technology

Private companies	3
CareFusion Corp. CareFusion Corp. Medical DistributorsDistribution Services CareFusion Corp. engages in the manufactures of medical equipment and device. The company was founded on February 4, 2009 and is headquartered in San Diego, CA.	Distribution Services
Turning Point Therapeutics, Inc. Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.	Health Technology
CareFusion Foundation

See company connections